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Lysosomal storage disorders (LSDs) are relatively rare inborn errors 
of metabolism, resulting from the accumulation of substrates within 
the lysosomes. They represent a group of more than 40 distinct genetic 
disorders. Most of these disorders are inherited in an autosomal recessive 
manner, except Fabry’s disease and mucopolysaccharidoses type II (MPS II) 
which are inherited in an X-linked recessive manner. Most disorders present 
clinically with multi-system involvement. Common clinical features involve 
bony dysplasia, hepatosplenomegaly, central nervous system dysfunction, 
haematological abnormalities, and coarse hair and facial features. There are 
many phenotypical similarities within the categories. Potential treatments 
for some of these disorders are available in the form of enzyme replacement 
therapy and bone marrow transplantation. PCR-sequencing methods were 
used for genetic investigation of 236 pediatric cases referred or diagnosed 
in our department over a period of 3 years from Nov 2009 to Nov 2012. 
Detailed clinical data, including sex, age of onset of disease, age at diagnosis, 
mode of presentation, family history, consanguinity rates, and high-risk 
screening results were collected. Biochemical analysis was done in different 
laboratories in abroad. 
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Diagnosis No %
Gaucher disease 29 12.3
Niemann-Pick disease A and B 28 11.9
Metachromatic leukodystrophy 14 5.9
Krabbe disease 5 2.1
GM1 Gangliosidosis 12 5
Tay-Sachs disease 31 13
Sandhoff disease 12 5
Mucopolysaccharidoses 74 31.4
 I-Cell disease/Mucolipidosis II 3 1.3
Lysosomal glycogen storage disease-Pompe’s disease 5 2.1
Activator Deficiency/GM2 Gangliosidosis 2 0.8
Alpha-mannosidosis 2 0.8
Cystinosis 3 1.3
Fabry disease 1 0.4
Farber disease 2 0.8
Fucosidosis 2 0.8
Neuronal Ceroid Lipofuscinoses 8 3.4
Wolman disease 3 1.3
Total 236 100
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